Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT), Norbert C. Gorin, Myriam Labopin, Vanderson Rocha, William Arcese, Meral Beksac, Eliane Gluckman, Olle Ringden, Tapani Ruutu, Josy Reiffers, Giuseppe Bandini, Michele Falda, Panagiotis Zikos, Roelf Willemze, Francesco Frassoni, Manuel Abecasis, Jitka Abráhamová, B. V. Afanassiev, Massimo Aglietta, Abdulaziz Alabdulaaly & 31 others Olga Aleinikova, E. Paolo Alessandrino, Salem H. Al Shemmari, D. Amadori, Sergio Amadori, Toren Amos, Marino Andolina, Reinhard Andreesen, Emanuele Angelucci, Jürgen Anhuf, Renate Arnold, Fikret Arpaci, Michel Attal, Wellington Azevedo, Hamdy A. Azim, Michele Baccarani, Andrea Bacigalupo, Tiziano Barbui, Mario Bargetzi, D. L. Barnard, H. H. Bartsch, André Baruchel, Camillo Battista, Jacques Olivier Bay, Mahmut Bayik, Ali Bazarbachi, Y. Beguin, Jose Luis Bello López, Istvan Benedek, Fabio Benedetti, Agnes Yong

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.

LanguageEnglish
Pages3043-3051
Number of pages9
JournalBlood
Volume102
Issue number8
DOIs
Publication statusPublished - 15 Oct 2003

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). / Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia : Influence of dose and stem cell source shows better outcome with rich marrow. In: Blood. 2003 ; Vol. 102, No. 8. pp. 3043-3051.
@article{ff0cacbb364144dd9e5937443209c3e0,
title = "Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow",
abstract = "Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95{\%} CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95{\%} CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95{\%} CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.",
author = "{The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT)} and Gorin, {Norbert C.} and Myriam Labopin and Vanderson Rocha and William Arcese and Meral Beksac and Eliane Gluckman and Olle Ringden and Tapani Ruutu and Josy Reiffers and Giuseppe Bandini and Michele Falda and Panagiotis Zikos and Roelf Willemze and Francesco Frassoni and Manuel Abecasis and Jitka Abr{\'a}hamov{\'a} and Afanassiev, {B. V.} and Massimo Aglietta and Abdulaziz Alabdulaaly and Olga Aleinikova and {Paolo Alessandrino}, E. and {Al Shemmari}, {Salem H.} and D. Amadori and Sergio Amadori and Toren Amos and Marino Andolina and Reinhard Andreesen and Emanuele Angelucci and J{\"u}rgen Anhuf and Renate Arnold and Fikret Arpaci and Michel Attal and Wellington Azevedo and Azim, {Hamdy A.} and Michele Baccarani and Andrea Bacigalupo and Tiziano Barbui and Mario Bargetzi and Barnard, {D. L.} and Bartsch, {H. H.} and Andr{\'e} Baruchel and Camillo Battista and Bay, {Jacques Olivier} and Mahmut Bayik and Ali Bazarbachi and Y. Beguin and L{\'o}pez, {Jose Luis Bello} and Istvan Benedek and Fabio Benedetti and Agnes Yong",
year = "2003",
month = "10",
day = "15",
doi = "10.1182/blood-2003-03-0665",
language = "English",
volume = "102",
pages = "3043--3051",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) 2003, 'Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow', Blood, vol. 102, no. 8, pp. 3043-3051. https://doi.org/10.1182/blood-2003-03-0665

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia : Influence of dose and stem cell source shows better outcome with rich marrow. / The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).

In: Blood, Vol. 102, No. 8, 15.10.2003, p. 3043-3051.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia

T2 - Blood

AU - The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT)

AU - Gorin, Norbert C.

AU - Labopin, Myriam

AU - Rocha, Vanderson

AU - Arcese, William

AU - Beksac, Meral

AU - Gluckman, Eliane

AU - Ringden, Olle

AU - Ruutu, Tapani

AU - Reiffers, Josy

AU - Bandini, Giuseppe

AU - Falda, Michele

AU - Zikos, Panagiotis

AU - Willemze, Roelf

AU - Frassoni, Francesco

AU - Abecasis, Manuel

AU - Abráhamová, Jitka

AU - Afanassiev, B. V.

AU - Aglietta, Massimo

AU - Alabdulaaly, Abdulaziz

AU - Aleinikova, Olga

AU - Paolo Alessandrino, E.

AU - Al Shemmari, Salem H.

AU - Amadori, D.

AU - Amadori, Sergio

AU - Amos, Toren

AU - Andolina, Marino

AU - Andreesen, Reinhard

AU - Angelucci, Emanuele

AU - Anhuf, Jürgen

AU - Arnold, Renate

AU - Arpaci, Fikret

AU - Attal, Michel

AU - Azevedo, Wellington

AU - Azim, Hamdy A.

AU - Baccarani, Michele

AU - Bacigalupo, Andrea

AU - Barbui, Tiziano

AU - Bargetzi, Mario

AU - Barnard, D. L.

AU - Bartsch, H. H.

AU - Baruchel, André

AU - Battista, Camillo

AU - Bay, Jacques Olivier

AU - Bayik, Mahmut

AU - Bazarbachi, Ali

AU - Beguin, Y.

AU - López, Jose Luis Bello

AU - Benedek, Istvan

AU - Benedetti, Fabio

AU - Yong, Agnes

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.

AB - Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich.

UR - http://www.scopus.com/inward/record.url?scp=0141889254&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-03-0665

DO - 10.1182/blood-2003-03-0665

M3 - Article

VL - 102

SP - 3043

EP - 3051

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -